United States

Analyst Research Report Snapshot


Capital Raise to Accelerate Proprietary Test Growth




RedChip Companies, Inc.


21 Oct 2013





Companies referenced:


Available for Immediate Download

On October 8, 2013, CGIX filed an S-1 to raise up to $46 million in common stock. We view this as positive, as a large capital raise would provide funds that can be used to accelerate growth of CGIX's proprietary genomic tests, leading to increased revenue and potentially reducing the time needed to reach profitability. With a larger cash reserve, CGIX can accelerate investment in sales and marketing, achieving faster market penetration and expand geographic coverage to establish a national footprint. Establishing a national footprint enables CGIX to better compete with Foundation Medicine (FMI), as CGIX can offer a more complete set of oncology Dx services than FMI.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.